Your browser doesn't support javascript.
loading
Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients.
Strouse, Christopher; Mott, Sarah L; Smith, Brian J; Magalhaes-Silverman, Margarida; Farooq, Umar; Zhan, Fenghuang; Jethava, Yogesh; Tricot, Guido.
Afiliación
  • Strouse C; Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA. Christopher-strouse@uiowa.edu.
  • Mott SL; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
  • Smith BJ; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
  • Magalhaes-Silverman M; Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA.
  • Farooq U; Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA.
  • Zhan F; Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical Center, Little Rock, AK, USA.
  • Jethava Y; Indiana Blood & Marrow Transplant, Indianapolis, IN, USA.
  • Tricot G; Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical Center, Little Rock, AK, USA.
Bone Marrow Transplant ; 59(1): 128-130, 2024 01.
Article en En | MEDLINE | ID: mdl-37816907

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Aged / Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Aged / Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos